25-hydroxyvitamin D levels, race, and the progression of kidney disease.

Black individuals have lower 25-hydroxyvitamin D [25(OH)D] levels and experience a disproportionate burden of ESRD compared with white individuals. Animal studies suggest that vitamin D has renoprotective effects. We evaluated the contribution of low 25(OH)D levels on incidence of ESRD using data from the Third National Health and Nutrition Examination Survey-linked Medicare claims files (n = 13,328). We included baseline (1988 through 1994) measurements of 25(OH)D and assessed the incidence of ESRD through July 31, 2001. Overall, 34% of non-Hispanic black individuals had 25(OH)D levels <15 ng/ml compared with 5% of non-Hispanic white individuals (P < 0.001). During a median of 9.1 yr, 65 participants developed ESRD. After adjustment for demographic, socioeconomic, and clinical and laboratory factors (including diabetes, hypertension, estimated GFR, and albuminuria), participants with 25(OH)D levels <15 ng/ml had a 2.6-fold greater incidence of ESRD than those with levels > or =15 ng/ml (incidence rate ratio 2.64; 95% confidence interval [CI] 1.00 to 7.05; P = 0.05). After adjustment for clinical covariates but not 25(OH)D levels, non-Hispanic black individuals had a 2.83-fold (95% CI 1.03 to 7.77) higher risk for developing ESRD compared with non-Hispanic white individuals. Additional adjustment for 25(OH)D levels reduced the risk by 58% (incidence rate ratio 1.77; 95% CI 0.38 to 8.21). In summary, low 25(OH)D levels associate with development of ESRD even after adjustment for multiple risk factors. Low 25(OH)D levels may account for a substantial proportion of the increased risk for ESRD experienced by black individuals.

[1]  C. Zoccali,et al.  Vitamin D levels and patient outcome in chronic kidney disease. , 2009, Kidney international.

[2]  B. Astor,et al.  25-Hydroxyvitamin D Levels and the Risk of Mortality in the General Population , 2008 .

[3]  D. V. von Mühlen,et al.  Differences in vitamin D status as a possible contributor to the racial disparity in peripheral arterial disease. , 2008, The American journal of clinical nutrition.

[4]  D. Reich,et al.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans , 2008, Nature Genetics.

[5]  E. Rimm,et al.  25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. , 2008, Archives of internal medicine.

[6]  P. Raggi,et al.  Serum 25-Hydroxyvitamin D Levels and the Prevalence of Peripheral Arterial Disease: Results from NHANES 2001 to 2004 , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Michael J. Pencina,et al.  Vitamin D Deficiency and Risk of Cardiovascular Disease , 2008, Circulation.

[8]  B. Kestenbaum,et al.  25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  A. Mitrakou,et al.  The Effects of Calcium and Vitamin D Supplementation on Blood Glucose and Markers of Inflammation in Nondiabetic Adults , 2007, Diabetes Care.

[10]  Keith C. Norris,et al.  Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. , 2007, Archives of internal medicine.

[11]  Edward Giovannucci,et al.  Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension , 2007, Hypertension.

[12]  J. Allison,et al.  Survival advantage of black patients with kidney disease after acute myocardial infarction. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[13]  J. Alexander,et al.  Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. , 2006, Kidney international.

[14]  S. Harris,et al.  Vitamin D and African Americans. , 2006, The Journal of nutrition.

[15]  G. Camussi,et al.  Treatment with 1, 25-Dihydroxyvitamin D3 Preserves Glomerular Slit Diaphragm-Associated Protein Expression in Experimental Glomerulonephritis , 2005, International journal of immunopathology and pharmacology.

[16]  N. Powe,et al.  Racial disparities in the optimal delivery of chronic kidney disease care. , 2005, The Medical clinics of North America.

[17]  H. Krumholz,et al.  Race and Renal Impairment in Heart Failure: Mortality in Blacks Versus Whites , 2005, Circulation.

[18]  Keith C. Norris,et al.  The prevalence of hypovitaminosis D among US adults: data from the NHANES III. , 2005, Ethnicity & disease.

[19]  B. Dawson-Hughes.  Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. , 2004, The American journal of clinical nutrition.

[20]  M. Sowers,et al.  Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. , 2004, Diabetes care.

[21]  S. Heymsfield,et al.  Lifestyle behaviors associated with lower risk of having the metabolic syndrome. , 2004, Metabolism: clinical and experimental.

[22]  Guilin Qiao,et al.  Vitamin D: a negative endocrine regulator of the renin–angiotensin system and blood pressure , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  E. Vittinghoff,et al.  Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. , 2003, Journal of the American Society of Nephrology : JASN.

[24]  H. Trivedi,et al.  Discrepancy in the Epidemiology of Nondiabetic Chronic Renal Insufficiency and End-Stage Renal Disease in Black and White Americans: The Third National Health and Nutrition Examination Survey and United States Renal Data System , 2003, American Journal of Nephrology.

[25]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[26]  T. Doi,et al.  22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  N. Powe,et al.  Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. , 2002, Journal of the American Society of Nephrology : JASN.

[28]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .

[29]  Tom Greene,et al.  Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  B. Dawson-Hughes,et al.  Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. , 2002, Bone.

[31]  槙林 弘之郎.  A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis , 2002 .

[32]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. , 2002, The Journal of clinical investigation.

[33]  H. Sollinger,et al.  1,25-(OH2)D3 Alters the Transforming Growth Factor β Signaling Pathway in Renal Tissue , 2001 .

[34]  G. Camussi,et al.  Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. , 2001, Kidney international.

[35]  H. Minne,et al.  Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. , 2001, The Journal of clinical endocrinology and metabolism.

[36]  H. Sollinger,et al.  1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. , 2001, The Journal of surgical research.

[37]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[38]  J. Mathews,et al.  A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. , 1999, Kidney international.

[39]  L. Chambless,et al.  A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: the Atherosclerosis Risk in Communities study. , 1999, Archives of internal medicine.

[40]  Arya M. Sharma,et al.  Ultraviolet B and blood pressure , 1998, The Lancet.

[41]  E. Ritz,et al.  Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. , 1998, Kidney international.

[42]  R. Lindsay,et al.  Resistance to Bone Resorbing Effects of PTH in Black Women , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  G. Beck,et al.  Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.

[44]  H. Rasmussen,et al.  Calcium absorption responses to calcitriol in black and white premenopausal women. , 1995, The Journal of clinical endocrinology and metabolism.

[45]  J. Kanis,et al.  Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure , 1995, BMJ.

[46]  B. Brenner,et al.  Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  M. Pasquali,et al.  No acceleration and possibly slower progression of renal failure during calcitriol treatment in predialysis chronic renal failure. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. , 1994, Vital and health statistics. Ser. 1, Programs and collection procedures.

[49]  R. Bouillon,et al.  Partial prevention of active Heymann nephritis by lα, 25 dihydroxyvitamin D3 , 1993, Clinical and experimental immunology.

[50]  P. Whelton,et al.  The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. , 1992, JAMA.

[51]  K. Maurer,et al.  Sample design: Third National Health and Nutrition Examination Survey. , 1992, Vital and health statistics. Series 2, Data evaluation and methods research.

[52]  S. Lillevang,et al.  Single and combined effects of the vitamin D analogue KH1060 and cyclosporin A on mercuric‐chloride‐induced autoimmune disease in the BN rat , 1992, Clinical and experimental immunology.

[53]  J. Lemire,et al.  1,25-Dihydroxyvitamin D3 Attenuates of Expression of Experimental Murine Lupus of MRL/1 Mice , 1992 .

[54]  J. Lemire,et al.  1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. , 1992, Autoimmunity.

[55]  R. Neuwirth,et al.  Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. , 1992, JAMA.

[56]  J. Adams,et al.  INCREASED SKIN PIGMENT REDUCES THE CAPACITY OF SKIN TO SYNTHESISE VITAMIN D3 , 1982, The Lancet.

[57]  M. Kodroff,et al.  Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure. , 1981, Pediatrics.

[58]  W. Loomis.  Skin-Pigment Regulation of Vitamin-D Biosynthesis in Man , 1967, Science.